Introduction
============

Visceral obesity, which is a key component of the metabolic syndrome, underlies the clustering of cardiovascular risk factors including hypertension, dyslipidemia, and glucose intolerance^[@bib1])^ and is related to the risk of cardiovascular morbidity and mortality^[@bib2])^. Visceral fat accumulation was also shown to be independently associated with the incidence of coronary artery diseases in several population-based studies^[@bib3],\ [@bib4])^. Moreover, several studies showed that the presence of metabolic syndrome was associated with the risk of cardiovascular morbidity and mortality even in subjects with type 2 diabetes (T2D)^[@bib5],\ [@bib6])^, indicating an important role for visceral adiposity in the development and progression of atherosclerotic cardiovascular disease (CVD) in such patients.

Alterations in vascular morphology and function can be assessed by ultrasonography as intima-media thickness (IMT) ("atherosclerosis") and vascular wall stiffness ("arteriosclerosis"), respectively^[@bib7])^, both of which are shown to predict adverse CVD events^[@bib8]--[@bib10])^. Importantly, carotid arterial stiffness predicts CVD mortality independent of simultaneously measured carotid IMT^[@bib11])^. Our research group previously reported that both IMT and stiffness parameter *β* of the carotid artery were higher in T2D subjects than in non-diabetic subjects^[@bib12],\ [@bib13])^. Previous community-based studies showed that presence of the metabolic syndrome was an independent determinant of both carotid IMT and stiffness^[@bib14])^. Visceral adiposity estimated by computed tomography (CT), magnetic resonance imaging (MRI), or waist-to-hip ratio was also shown to be related to IMT^[@bib15])^ and distensibility/stiffness^[@bib16]--[@bib18])^ of the carotid artery in healthy or non-diabetic subjects. However, regarding the link between visceral adiposity and the risk of CVD, only a few studies have focused on the differential impacts of visceral adiposity on vascular thickness and stiffness in subjects with T2D^[@bib19]--[@bib21])^.

Recently, the dual bioelectrical impedance analysis (dual BIA) instrument was developed for measuring visceral fat area (VFA), and its clinical utility in detecting severity of the metabolic syndrome and effectiveness of weight reduction therapy in obese patients has been confirmed in pilot studies^[@bib22],\ [@bib23])^. Apart from the study of Bouchi *et al.*^[@bib24])^, which used aortic pulse wave velocity (PWV), no study has so far investigated the association between VFA estimated by dual BIA and surrogate markers of CVD.

Aim
===

In this study, we evaluated visceral adiposity using a dual BIA instrument and investigated the clinical impact of visceral adiposity on arterial wall thickness and stiffness in patients with T2D in a cross-sectional manner.

Methods
=======

Subjects
--------

We consecutively enrolled 161 subjects with T2D (92 men and 69 women) who were admitted to the Diabetes Center of the Osaka City University Hospital for the purpose of glycemic control, education, and/or evaluation of diabetic complications between February 2013 and September 2014. T2D was diagnosed based on the criteria of the American Diabetes Association^[@bib25])^. Subjects with type 1 diabetes and other types of diabetes were excluded from this study. We also excluded subjects with waist circumference (WC) \<130 cm because their VFA cannot be measured by a dual BIA instrument. In our analyses, a smoker was defined as a current smoker. All subjects provided written informed consent, and the ethical review board of our institution approved this study protocol (No. 164).

Physical and Laboratory Measurements
------------------------------------

Blood pressure was determined by the conventional cuff method with an automatic sphygmomanometer after subjects had rested for at least 15 min. WC was measured to the nearest centimeter at the level of the umbilicus in a standing position at the end of gentle expiration. Blood was drawn after an overnight fast, and biochemical parameters were analyzed by a standard laboratory method as previously described^[@bib26])^.

Measurement of VFA by Dual BIA
------------------------------

VFA, along with subcutaneous fat area (SFA), was measured by a dual BIA instrument (HDS-2000, Omron Healthcare Co. Ltd., Kyoto, Japan) in the morning after an overnight fast. Dual BIA calculates the cross-sectional area of intra-abdominal fat at the level of the umbilicus based on two different impedance values, as described elsewhere in detail^[@bib22],\ [@bib23])^. A close correlation between VFA determined by dual BIA and that obtained by a CT scan was previously demonstrated^[@bib22],\ [@bib23])^.

Measurement of carotid IMT and stiffness parameter *β* by ultrasonography
-------------------------------------------------------------------------

IMT and stiffness parameter *β* of the common carotid artery were measured by an ultrasonic phase-locked echo-tracking system, which was equipped with a high-resolution real-time 13-MHz linear scanner (Prosound F75; Hitachi Aloka Medical, Ltd., Tokyo, Japan) as previously reported^[@bib13],\ [@bib27])^. In brief, IMT of bilateral carotid arteries was measured at the sites of the most advanced atherosclerotic lesions in longitudinal and transverse projections. The greatest IMT, including plaque, was utilized as a marker of atherosclerotic changes in the carotid arteries.

Stiffness parameter *β*, an index of arterial wall stiffness, was calculated as ln (Ps/Pd) × Dd/(Ds − Dd), where Ps and Pd are systolic and diastolic blood pressure and Ds and Dd are systolic and diastolic inner diameters of the carotid artery, respectively^[@bib12],\ [@bib13])^. The greater stiffness parameter *β* between the left and right carotid arteries was utilized as a marker of arteriosclerotic changes. Those measurements were performed in the morning after an overnight fast and with a resting period of 15 min in a quiet room airconditioned at 25°C throughout the year. The subjects were also refrained from smoking, alcohol, and beverages containing caffeine a few hours before measurement according to the recommendations of the international task force^[@bib28])^.

Statistics
----------

Data were expressed as number (%), mean ± standard deviation (SD), or median (interquartile range) as appropriate. For comparisons between men and women, the χ^2^-test, Student\'s *t*-test, or Wilcoxon rank-sum test was performed as appropriate. Simple and multiple linear regression analyses were performed to evaluate the relationship between stiffness parameter *β* or IMT and various clinical parameters, including obesity-related indices \[body mass index (BMI), WC, VFA, and SFA\]. Skewed parameters, including plasma triglycerides levels, were logarithmically transformed before regression analyses. In multiple regression analyses, stiffness parameter *β* or IMT was the dependent variable, and obesity-related indices (BMI, WC, VFA, or SFA), age, systolic blood pressure, glycated hemoglobin A1c (HbA1c) level, serum creatinine level, high-density lipoprotein (HDL) cholesterol level, low-density lipoprotein (LDL) cholesterol level, smoking status, presence of treatment with statins, and presence of treatment with angiotensin-II receptor blockers or angiotensin-converting enzyme inhibitors (ARB/ACEI) were the independent variables. A *p* value of \<0.05 was considered to indicate statistical significance. Statistical analyses were performed using the JMP^®^ 10 software (SAS Institute Inc., Cary, NC).

Results
=======

Clinical Characteristics of the Subjects
----------------------------------------

The clinical characteristics of the total study population as well as men and women separately are shown in **[Table 1](#T1){ref-type="table"}**. Twenty (12%) subjects with T2D were treated with dietary therapy alone; 119 (74%) with oral hypoglycemic agents, including 90 with dipeptidyl peptidase-4 inhibitors, 62 with sulfonylureas, 60 with biguanides, 22 with thiazolidinediones, 19 with *α*-glucosidase inhibitors, 5 with insulin secretagogues (glinides); 22 (14%) with insulin alone; 26 (16%) with a combination of insulin and oral hypoglycemic agents; and 3 (2%) with glucagon-like peptide-1 analogs. The mean age and known duration of diabetes in the study population were 61 years and 13.9 years, respectively. There were significantly more male smokers than female smokers. Plasma HDL cholesterol levels were lower in men than in women. Age, duration of diabetes, BMI, WC, blood pressure, presence of treatment with statins or ARB/ACEI, renal function, glycemic control, and lipid profiles other than HDL cholesterol were not significantly different between men and women.

###### Clinical characteristics, abdominal adiposity, and carotid stiffness and thickness in all subjects with type 2 diabetes as well as in men and women separately

                                     All                Men               Women             *p*
  ---------------------------------- ------------------ ----------------- ----------------- -------
  *N*                                161                92                69                
  Age (years)                        61 ± 14            60 ± 13           63 ± 14           0.204
  Duration of diabetes (years)       13.9 ± 11.1        14.6 ± 11.4       13.0 ± 10.6       0.394
  BMI (kg/m^2^)                      27.1 ± 5.8         26.7 ± 5.3        27.7 ± 6.5        0.273
  WC (cm)                            92 ± 14            92 ± 13           91 ± 14           0.631
  Systolic blood pressure (mmHg)     132 ± 19           130 ± 16          136 ± 22          0.055
  Diastolic blood pressure (mmHg)    76 ± 11            77 ± 10           74 ± 11           0.074
  Smoker *n* (%)                     29 (18.0)          24 (34.8)         5 (9.3)           0.001
  Statin *n* (%)                     66 (41.0)          33 (35.9)         33 (47.8)         0.127
  ARB/ACEI *n* (%)                   65 (40.4)          38 (41.3)         27 (39.1)         0.871
  Fasting glucose (mg/dL)            131 ± 39           131 ± 40          130 ± 38          0.711
  HbA1c (%)                          8.6 ± 1.9          8.6 ± 1.9         8.6 ± 1.9         0.894
  Immunoreactive insulin (*µ*U/mL)   7.4 (4.6--11.55)   7.1 (4.4--11.1)   7.5 (4.6--11.9)   0.407
  Serum creatinine (mg/dL)           1.02 ± 0.85        1.13 ± 0.73       0.88 ± 0.97       0.062
  Triglycerides (mg/dL)              126 (92--163)      130 (100--171)    116 (85--159)     0.179
  HDL-cholesterol (mg/dL)            43 ± 12            40 ± 10           46 ± 14           0.004
  LDL-cholesterol (mg/dL)            115 ± 39           114 ± 42          115 ± 36          0.896
  VFA (cm^2^)                        94.7 ± 50.1        99.3 ± 53.2       88.7 ± 45.3       0.186
  SFA (cm^2^)                        216.7 ± 109.2      208.2 ± 100.1     228.0 ± 120.1     0.255
  Stiffness parameter *β*            11.6 ± 5.3         11.0 ± 4.7        12.3 ± 5.9        0.159
  IMT (mm)                           1.05 ± 0.34        1.03 ± 0.37       1.08 ± 0.30       0.377

Data are expressed as mean ± SD, median (interquartile range), or *n* (%). *P*-values were determined by Student\'s *t*-test, Wilcoxon rank-sum test, or *χ*^2^-test, as appropriate. Abbreviations: BMI, body mass index; WC, waist circumference; smoker, prevalence of current smokers; statin, prevalence of subjects treated with statins; ARB/ACEI, prevalence of subjects treated with angiotensin-II receptor antagonists or ACE inhibitors; HbA1c, glycated hemoglobin A1c level; HDL, high-density lipoprotein; LDL, low-density lipoprotein; VFA, visceral fat area; SFA, subcutaneous fat area; IMT, intima-media thickness.

Abdominal Adiposity and Carotid Arterial Stiffness and Thickness in the T2D Subjects
------------------------------------------------------------------------------------

The mean VFAs estimated by dual BIA in men and women were 99.3 ± 53.2 cm^2^ and 88.7 ± 45.3 cm^2^, respectively, without a significant difference between the sexes (**[Table 1](#T1){ref-type="table"}**). Similarly, no significant difference in SFA was found between the sexes. In good agreement with a pilot study in obese patients^[@bib23])^, VFA estimated by dual BIA was closely correlated with BMI (*r* = 0.807, *p* \< 0.001) and WC (*r* = 0.881, *p* \< 0.001) in subjects with T2D (**[Supplemental Table 1](#T4){ref-type="table"}**). Moreover, VFA by dual BIA showed significant correlation with metabolic parameters, such as plasma immunoreactive insulin levels (*r* = 0.415, *p* \< 0.001) and triglycerides levels (*r* = 0.331, *p* \< 0.001) in all subjects and with HDL cholesterol levels (*r* = −0.483, *p* \< 0.001) and diastolic blood pressure (*r* = 0.280, *p* = 0.022) in women (**[Supplemental Table 1](#T4){ref-type="table"}**).

The mean value of carotid stiffness parameter *β* in the total population was 11.6 (range, 2.5--34.9), and there was no significant difference between men and women. The mean carotid IMT for the total population was 1.05 mm (range, 0.37--2.41), without a significant difference between the sexes (**[Table 1](#T1){ref-type="table"}**).

Association of Visceral Adiposity with Carotid Stiffness and Thickness
----------------------------------------------------------------------

We first examined the association of carotid stiffness or thickness with obesity-related indices, including BMI, WC, VFA, and SFA, and other risk factors for CVD by simple linear regression analyses separately in men and women. In men, stiffness parameter *β* was positively correlated with WC and VFA but not with BMI or SFA (**[Fig. 1](#F1){ref-type="fig"}** and **[Table 2](#T2){ref-type="table"}**). IMT was negatively correlated with BMI, WC, and SFA but not with VFA (**[Supplemental Fig. 1](#F3){ref-type="fig"}** and **[Table 2](#T2){ref-type="table"}**). In contrast, in women, none of the obesity-related indices were significantly correlated with stiffness parameter *β* (**[Supplemental Fig. 2](#F4){ref-type="fig"}**) or IMT (**[Supplemental Fig. 3](#F5){ref-type="fig"}**) (**[Table 2](#T2){ref-type="table"}**).

![Association of visceral fat area (VFA) (a), subcutaneous fat area (SFA) (b), body mass index (BMI) (c), and waist circumference (WC) (d) with stiffness parameter *β* of the common carotid artery in men with type 2 diabetes (T2D)\
In men with T2D, VFA (*r* = 0.290, *p* = 0.019) and WC (*r* = 0.257, *p* = 0.044), but not SFA (*r* = 0.186, *p* = 0.139) and BMI (*r* = 0.145, *p* = 0.248), showed significant positive correlations with stiffness parameter *β*.](jat-23-1067-g001){#F1}

###### Correlations between carotid stiffness and thickness and clinical variables in subjects with type 2 diabetes

                             Stiffness parameter *β*                         IMT                                                                                            
  -------------------------- ----------------------------------------------- ---------------------------------------------- ----------------------------------------------- -----------------------------------------------
  Age                              0.335[\*\*](#tfn2){ref-type="table-fn"}       0.323[\*](#tfn1){ref-type="table-fn"}            0.425[\*\*](#tfn2){ref-type="table-fn"}         0.358[\*\*](#tfn2){ref-type="table-fn"}
  BMI                          0.145                                           0.072                                          −0.267[\*](#tfn1){ref-type="table-fn"}        −0.098
  WC                             0.257[\*](#tfn1){ref-type="table-fn"}         0.153                                          −0.265[\*](#tfn1){ref-type="table-fn"}        −0.073
  VFA                            0.290[\*](#tfn1){ref-type="table-fn"}         0.183                                        −0.173                                          −0.098
  SFA                          0.186                                           0.048                                          −0.259[\*](#tfn1){ref-type="table-fn"}        −0.043
  Systolic blood pressure      0.094                                         −0.072                                           0.013                                           0.165
  Diastolic blood pressure     0.021                                         −0.140                                         −0.115                                          −0.031
  Fasting glucose            −0.092                                            0.035                                        −0.011                                          −0.161
  HbA1c                      −0.084                                            0.165                                        −0.091                                          −0.145
  Serum creatinine             0.074                                           0.096                                        −0.043                                            0.114
  Log \[triglycerides\]        0.090                                           0.158                                        −0.028                                          −0.012
  HDL-cholesterol              0.070                                             −0.424[\*\*](#tfn2){ref-type="table-fn"}   −0.149                                          −0.078
  LDL-cholesterol            −0.155                                          −0.196                                           0.024                                           0.046

Values are correlation coefficients determined by simple regression analyses.

*p* \< 0.05;

*p* \< 0.01.

BMI, body mass index; WC, waist circumference; HbA1c, glycated hemoglobin A1c level; HDL, high-density lipoprotein; LDL, low-density lipoprotein; VFA, visceral fat area; SFA, subcutaneous fat area; IMT, intima-media thickness.

Among the other known risk factors for CVD, including age, blood pressure, fasting glucose level, HbA1c level, serum creatinine level, triglycerides level, HDL cholesterol level, and LDL cholesterol level, age was significantly correlated with stiffness parameter *β* and IMT in both men and women. In addition, an inverse correlation between HDL cholesterol level and stiffness parameter *β* was found in women (**[Table 2](#T2){ref-type="table"}**). None of the other cardiometabolic risk factors were significantly associated with stiffness parameter *β* or IMT in each sex, presumably because a large number of the subjects were receiving medications for hypertension, dyslipidemia, and diabetes.

Multivariate Analyses of the Determinants for Carotid Stiffness and Thickness
-----------------------------------------------------------------------------

Age was correlated not only positively with carotid stiffness parameter *β* and IMT but also negatively with obesity-related indices (BMI, *r* = −0.387, *p* \< 0.001; WC, *r* = −0.305, *p* = 0.001; VFA, *r* = −0.249, *p* = 0.001; SFA, *r* = −0.381, *p* \< 0.001), suggesting that the correlations of obesity-related indices with stiffness parameter *β* and IMT were confounded at least by age. Therefore, multiple regression analyses were performed to identify independent associations of visceral adiposity with carotid stiffness and thickness after adjusting for age and other potential confounders, including systolic blood pressure, HbA1c level, serum creatinine level, HDL cholesterol level, LDL cholesterol level, smoking status, and presence of treatment with statins and ARB/ACEI (**[Table 3](#T3){ref-type="table"}**). Among all the variables, obesity-related indices, such as VFA (*β* = 0.417, *p* = 0.001), SFA (*β* = 0.488, *p* = 0.001), WC (*β* = 0.527, *p* \< 0.001), and BMI (*β* = 0.443, *p* = 0.002), along with age, were independently and positively associated with stiffness parameter *β* in men (**[Table 3](#T3){ref-type="table"}**), whereas none of these obesity-related indices were found to be a determinant of IMT (**[Table 3](#T3){ref-type="table"}**). In women, none of the obesity-related indices were independently associated with carotid stiffness parameter *β* or IMT (**[Table 3](#T3){ref-type="table"}**).

###### Associations of obesity-related indices with carotid stiffness and thickness in subjects with type 2 diabetes

                  Stiffness parameter *β*                   IMT              
  --------------- ----------------------------------------- ------- -------- -------
  BMI (kg/m^2^)   0.443[\*\*](#tfn3){ref-type="table-fn"}   0.080   −0.141   0.013
  WC (cm)         0.527[\*\*](#tfn3){ref-type="table-fn"}   0.048   −0.106   0.027
  VFA (cm^2^)     0.417[\*\*](#tfn3){ref-type="table-fn"}   0.159   −0.105   0.024
  SFA (cm^2^)     0.488[\*\*](#tfn3){ref-type="table-fn"}   0.103   −0.139   0.080

Values are standard regression coefficients determined by multiple regression analyses. In men or women, body mass index (BMI), waist circumferences (WC), visceral fat area (VFA), or subcutaneous fat area (SFA) was set as an independent variable after adjustment for age, systolic blood pressure, HbA1c level, serum creatinine level, high-density lipoprotein (HDL)-cholesterol, low-density lipoprotein (LDL)-cholesterol, smoking status, and presence of treatment with statins and ARB/ACEI.

*p* \< 0.01.

Association between Carotid Stiffness and Thickness in Men
----------------------------------------------------------

Finally, to understand the reason why visceral adiposity is associated with carotid arterial stiffness differently from thickness in men with T2D, we examined the association between carotid stiffness parameter *β* and IMT. We found no significant correlation between stiffness parameter *β* and IMT in men (**[Fig. 2](#F2){ref-type="fig"}**). Then, we divided the men into four groups according to the median values of carotid stiffness parameter *β* (9.8) and IMT (0.93 mm) and compared clinical parameters between the men with high IMT but low stiffness parameter *β* ("IMT-advanced") and those with high stiffness parameter *β* but low IMT ("stiffness-advanced"). As expected from the results of multivariate analyses, subjects in the stiffness-advanced group were much more obese with greater BMI, WC, VFA, and SFA than those in the IMT-advanced group (**[Supplemental Table 2](#T5){ref-type="table"}**). In contrast, the other parameters, including age, duration of diabetes, blood pressure, medications, glycemic control, and lipid profile, were similar between the groups (**[Supplemental Table 2](#T5){ref-type="table"}**).

![Association between stiffness parameter *β* and intima-media thickness (IMT) of the common carotid artery in men with type 2 diabetes\
In men with type 2 diabetes, stiffness parameter *β* was not significantly correlated with IMT (*r* = −0.048, *p* = 0.705).](jat-23-1067-g002){#F2}

Discussion
==========

This study explored the relationship between visceral adiposity and carotid arterial stiffness and thickness in patients with T2D and demonstrated that VFA estimated by dual BIA was closely associated with carotid stiffness parameter *β*, but not with IMT, in men. Importantly, the association between VFA and carotid stiffness was independent of known CVD risk factors. Moreover, in women, visceral adiposity was associated with neither carotid stiffness parameter *β* nor IMT. These findings indicate an important role of visceral fat accumulation in the pathogenesis of arteriosclerosis or functional changes in arteries in men with T2D.

We did not find a significant association between visceral adiposity and IMT in our male population. This finding is in disagreement with previous studies showing a positive association of visceral adiposity with IMT^[@bib15],\ [@bib20],\ [@bib29]--[@bib31])^. There are at least two possible explanations for the conflicting results. First, the methods of estimating visceral fat mass were different. A number of studies using ultrasonography have associated visceral fat thickness with IMT^[@bib20],\ [@bib29]--[@bib31])^, whereas a few studies using CT, the gold standard for quantifying visceral fat mass, have provided inconsistent results on the relationship between VFA and IMT^[@bib15],\ [@bib21])^. Although both visceral fat thickness measured by ultrasonography^[@bib32])^ and VFA measured by dual BIA^[@bib22],\ [@bib23])^ are reportedly well correlated with VFA determined by CT, estimates of local fat thickness and the total cross-sectional area of visceral fat may be differently related to clinical parameters. Second, there were large differences between the study populations. The subjects of the previous studies were healthy^[@bib15],\ [@bib31])^, mostly non-diabetic^[@bib29],\ [@bib30])^, or much younger patients with T2D than those included in our study^[@bib20])^. In contrast, our study included subjects with T2D with a relatively higher age and a long duration of the disease. In this regard, Konishi *et al.*^[@bib21])^ did not find a significant relationship between VFA and IMT in patients with T2D whose mean age, duration of diabetes, and IMT were similar to those of our subjects.

Despite no significant association between VFA and IMT, this study clearly demonstrated a positive correlation between VFA and carotid stiffness parameter *β* in men with T2D. The association between visceral adiposity and carotid arterial stiffness measured by ultrasonography has been demonstrated in healthy subjects^[@bib16])^ and the general population^[@bib17])^. Presence of the metabolic syndrome^[@bib14])^ or high waist-to-hip ratio^[@bib18])^ was also associated with increased carotid arterial stiffness in non-diabetic women^[@bib18])^ and community-dwelling subjects^[@bib14])^. There are few studies investigating the impact of visceral fat mass on carotid arterial stiffness in patients with T2D^[@bib19],\ [@bib21])^. Diamant *et al.*^[@bib19])^ showed that carotid stiffness expressed as the distensibility coefficient was inversely associated with VFA measured by MRI in 16 patients with uncomplicated T2D but not in age-matched healthy controls. Konishi *et al*.^[@bib21])^ also demonstrated that VFA measured by CT was independently associated with carotid stiffness parameter *β* in 151 patients with T2D but not in age-matched non-diabetic controls. These studies indicate that a strong association between abdominal obesity or visceral adiposity and carotid arterial stiffness can be observed in a wide range of subjects from the general population to patients with T2D and that this association is stronger in subjects with T2D than in those without it.

Differential impact of cardiovascular risk factors on arterial stiffness and IMT were also observed in Japanese patients with T2D^[@bib21],\ [@bib33],\ [@bib34])^. Consistent with our results, several studies reported that the association with obesity-related measures was different between arterial stiffness and IMT^[@bib21],\ [@bib35])^. In Japanese T2D patients, VFA was significantly associated with carotid stiffness parameter *β* but not with carotid IMT^[@bib21])^. Moreover, BMI was a strong determinant of aortic PWV, but not carotid IMT, in obese T2D patients in the U.S^[@bib35])^. On the other hand, dyslipidemia^[@bib21],\ [@bib33])^ and hyperglycemia^[@bib34],\ [@bib35])^, but not obesity-related indices, were preferentially associated with carotid IMT in subjects with T2D. In addition, we found that only obesity-related indices were significantly different between the men with higher stiffness but lower IMT and the men with lower stiffness but higher IMT. These observations indicate a preferential association of obesity with arterial stiffness over arterial thickness in T2D. Because the correlation between IMT and stiffness index is relatively low^[@bib14])^, we speculate the dominant role of obesity in arterial stiffening regardless of arterial wall thickness.

Insulin resistance may be one of the mechanisms linking visceral adiposity to arterial stiffness. Our research group has extensively investigated the association between insulin resistance and carotid arterial stiffness and thickness in patients with T2D^[@bib12],\ [@bib36]--[@bib39])^. We^[@bib12])^ and others^[@bib16],\ [@bib40])^ showed that insulin sensitivity evaluated by the euglycemic hyperinsulinemic clamp technique was inversely associated with arterial stiffness of the carotid^[@bib12],\ [@bib40])^ and femoral^[@bib12],\ [@bib16])^ arteries in healthy women^[@bib16])^ and subjects with T2D^[@bib12],\ [@bib40])^. Moreover, we found that improved carotid stiffness parameter *β* was associated with increased clamp-measured insulin sensitivity after short-term exercise^[@bib39])^ and with the increase in adiponectin levels after treatment with an insulin sensitizer pioglitazone or metformin^[@bib38])^ in patients with T2D. On the other hand, only a few studies^[@bib36],\ [@bib41])^ including ours^[@bib36])^ showed significant and inverse relationship between carotid IMT and insulin sensitivity as determined by the euglycemic hyperinsulinemic clamp in patients with T2D. In T2D subjects of our previous studies, correlation with clamp-measured insulin sensitivity index was higher in carotid stiffness parameter *β* (*r* = −0.393, *p* = 0.002)^[@bib12])^ than in IMT (*r* = −0.225, *p* = 0.014)^[@bib36])^. Because visceral adiposity evidently underlies insulin resistance^[@bib1])^, it is conceivable that accumulated visceral fat predominantly affects carotid arterial stiffness over wall thickness, at least partly through impaired insulin sensitivity in T2D men. Nevertheless, several studies indicate possible implications of adipocytokines or inflammatory factors, such as adiponectin^[@bib21],\ [@bib38])^, leptin^[@bib42])^, TNF-*α*^[@bib21])^, C-reactive protein^[@bib19])^, and interleukin-6^[@bib19])^, in carotid arterial stiffness in subjects with T2D. Further studies are needed to completely understand how visceral adiposity regulates arterial stiffness and differently impacts carotid stiffness and thickness in diabetic individuals.

In contrast to men, women exhibited no significant association between visceral adiposity and carotid arterial stiffness in this study. Sex hormone is one of the possible explanations. Arterial stiffness is known to be affected by age-related loss of estrogen action in women^[@bib43],\ [@bib44])^. Moreover, the detrimental impact of diabetes on aortic and carotid arterial stiffness was reported to be greater in women than in men^[@bib45])^. However, vascular endothelial function and arterial stiffness could be fluctuated with a menstrual cycle in premenopausal women^[@bib46])^. Because we performed vascular measurements without considering menstrual cycle, it is possible that we could not detect the association between visceral adiposity and stiffness parameter *β* in women in this study.

We noticed that SFA and VFA were differently correlated with IMT in men, but not in women, in univariate regression, although this correlation disappeared after multivariate adjustment. Similarly, univariate models showed different association of SFA and VFA with stiffness parameter *β* in men, but not in women, although both were independent explanatory factors for stiffness parameter *β* in multivariate models. We do not know the importance of these univariate findings nor the precise mechanisms. However, these findings may be related to the differential roles of SFA and VFA on insulin resistance, abnormal cytokine profile^[@bib1])^ and arterial wall thickness^[@bib29]--[@bib31])^ and stiffness^[@bib16],\ [@bib47])^, as shown in the previous studies, and also indicate a possible difference in the adiposity-artery relationship between the sexes.

This study provides a clinical evidence supporting the critical role of visceral adiposity in carotid arterial stiffness in patients with T2D. Compared with the precedent studies in T2D subjects^[@bib19],\ [@bib21])^, novel findings of this study are that visceral adiposity is strongly associated with stiffness as a functional property, rather than with wall thickness as a morphological property, of the carotid artery and that the association is found only in men. Because both carotid IMT and arterial stiffness independently predict CVD events^[@bib8]--[@bib10])^, this study indicates that visceral adiposity regulates arterial stiffness, regardless of arterial thickness, to potentially modulate the risk of CVDs in patients with T2D. This study further proposes that VFA, which can be repeatedly assessed by the dual BIA instrument, is a potential marker for monitoring the effect of weight-reducing therapy on vascular health in patients with obesity and diabetes.

This study has several limitations. First, because this was a cross-sectional study, a causal relationship between visceral fat accumulation and carotid arterial stiffness could not be confirmed. Second, our subjects were receiving anti-hypertensive drugs and statins, which could have affected arterial stiffness and the related atherosclerotic risk factors. To minimize the effect of such treatments, we adjusted for the presence of these therapies in the multivariate analyses. Third, because the subjects with T2D were hospitalized largely with inadequate glycemic control, the current results cannot be generalized. Fourth, non-diabetic controls were not used to compare the findings, and we could not confirm that carotid stiffness parameter *β* was increased in subjects with T2D. In our previous study, we used the same procedure to confirm that carotid stiffness parameter *β* was higher in T2D patients than in non-diabetic subjects^[@bib37])^. Finally, visceral adiposity was evaluated not by CT, the gold-standard method, but by dual BIA. However, previous studies reported a good correlation between VFA values obtained by CT and dual BIA^[@bib22],\ [@bib23])^.

Conclusion
==========

This study demonstrates that visceral adiposity is independently associated with stiffness parameter *β* of the carotid artery in men with T2D. Our data may indicate that the accumulated visceral fat preferentially affects arterial stiffness, known as an independent predictor of CVD. Further studies are required to identify the factors linking visceral fat accumulation and arterial stiffening in diabetes. In addition, interventional studies are warranted to clarify whether reduction of visceral adiposity could reverse arterial stiffness, a functional change of the arterial wall, in patients with diabetes at a high risk of CVDs.
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![Association of visceral fat area (VFA) (a), subcutaneous fat area (SFA) (b), body mass index (BMI) (c), and waist circumference (WC) (d) with intima-media thickness (IMT) of the common carotid artery in men with type 2 diabetes\
In men with type 2 diabetes, SFA (*r* = −0.259, *p* = 0.023), BMI (*r* = −0.267, *p* = 0.019) and WC (*r* = −0.265, *p* = 0.023), but not VFA (*r* = −0.173, *p* = 0.134), showed significant correlations with IMT.](jat-23-1067-g003){#F3}

![Association of visceral fat area (VFA) (a), subcutaneous fat area (SFA) (b), body mass index (BMI) (c), and waist circumference (WC) (d) with stiffness parameter *β* of the common carotid artery in women with type 2 diabetes\
In women with type 2 diabetes, none of the obesity-related indices were significantly correlated with stiffness parameter *β* (VFA, *r* = 0.183, *p* = 0.191; SFA, *r* = 0.048, *p* = 0.735; BMI, *r* = 0.072, *p* = 0.610; WC, *r* = 0.153, *p* = 0.288).](jat-23-1067-g004){#F4}

![Association of visceral fat area (VFA) (a), subcutaneous fat area (SFA) (b), body mass index (BMI) (c), and waist circumference (WC) (d) with intima-media thickness (IMT) of the common carotid artery in women with type 2 diabetes\
In women with type 2 diabetes, none of the obesity-related indices were significantly correlated with carotid IMT (VFA, *r* = −0.046, *p* = 0.737; SFA, *r* = −0.043, *p* = 0.753; BMI, *r* = −0.098, *p* = 0.468; WC, *r* = −0.073, *p* = 0.598).](jat-23-1067-g005){#F5}

###### Correlations of visceral fat area with obesity-related indices and metabolic parameters in subjects with type 2 diabetes

                                   ALL       Men       Women                         
  -------------------------------- --------- --------- --------- --------- --------- ---------
  Age                              −0.249      0.001   −0.255      0.014   −0.225      0.063
  BMI                                0.807   \<0.001     0.825   \<0.001     0.852   \<0.001
  WC                                 0.881   \<0.001     0.893   \<0.001     0.879   \<0.001
  Systolic blood pressure            0.086     0.285     0.034     0.755     0.193     0.117
  Diastolic blood pressure           0.166     0.039     0.065     0.545     0.280     0.022
  Fasting glucose                    0.077     0.336     0.044     0.679     0.128     0.302
  HbA1c                            −0.029      0.715   −0.121      0.251     0.117     0.344
  Log \[immunoreactive insulin\]     0.415   \<0.001     0.461   \<0.001     0.385     0.002
  Log \[triglycerides\]              0.331   \<0.001     0.281     0.007     0.401     0.001
  HDL-cholesterol                  −0.284    \<0.001   −0.101      0.338   −0.483    \<0.001
  LDL-cholesterol                  −0.021      0.793   −0.059      0.577     0.050     0.683

*r*, correlation coefficients determined by simple regression analyses. BMI, body mass index; WC, waist circumference; HbA1c, glycated hemoglobin A1c level; HDL, high-density lipoprotein; LDL, low-density lipoprotein.

###### Comparison of obesity-related indices and clinical parameters between IMT-advanced and Stiffness-advanced subjects in men with type 2 diabetes

                                     Stiffness *β* -High   IMT-High            *p*
  ---------------------------------- --------------------- ------------------- -------
  *N*                                18                    18                  
  Age (years)                        57.8 ± 10.8           63.4 ± 11.4         0.139
  Duration of diabetes (years)       14.2 ± 2.5            10.0 ± 2.5          0.249
  BMI (kg/m^2^)                      28.5 ± 5.3            23.9 ± 4.6          0.009
  WC (cm)                            96 ± 12               86 ± 9              0.010
  VFA (cm^2^)                        116.4 ± 58.2          78.4 ± 38.6         0.027
  SFA (cm^2^)                        237.9 ± 89.1          149.8 ± 71.2        0.002
  Systolic blood pressure (mmHg)     133 ± 20              131 ± 17            0.779
  Diastolic blood pressure (mmHg)    82 ± 12               78 ± 9              0.213
  Smoker *n* (%)                     4 (22.2)              7 (38.9)            0.275
  Statin use *n* (%)                 4 (22.2)              6 (33.3)            0.456
  Insulin use *n* (%)                8 (44.4)              5 (27.8)            0.296
  ARB/ACEI use *n* (%)               6 (33.3)              9 (50.0)            0.309
  Fasting glucose (mg/dL)            138 ± 10              125 ± 10            0.360
  HbA1c (%)                          9.1 ± 2.8             8.5 ± 1.7           0.420
  Immunoreactive insulin (*µ*U/mL)   8.2 (3.5 -- 12.2)     7.2 (4.6 -- 11.1)   0.882
  Serum creatinine (mg/dL)           1.37 ± 1.03           1.12 ± 0.60         0.388
  Triglycerides (mg/dL)              150 (104 -- 210)      117 (85 -- 153)     0.164
  HDL-cholesterol (mg/dL)            40.6 ± 9.3            37.9 ± 7.0          0.330
  LDL-cholesterol (mg/dL)            125 ± 43              114 ± 47            0.426

Data are expressed as mean ± SD, median (interquartile range), or *n* (%). *P*-values were determined by Student\'s *t*-test, Wilcoxon rank-sum test, or *χ*^2^-test, as appropriate. Abbreviations are the same as in [Table 1](#T1){ref-type="table"}.
